Education:
Fellowship
Stem Cell Transplantation and CellularTherapies
University of Texas MD Anderson CancerCenter
Houston, TX
Hematology/Oncology
Virginia CommonwealthUniversity
Richmond, VA
Residency
Internal Medicine
Virginia Commonwealth University
Richmond, VA
Medical School
Doctor of Medicine
Weill Cornell Medicine
Qatar
Board Certification(s):
Internal Medicine
Medical Oncology
Hematology
Clinical/Research Interests:
1-Hematopoietic stem cell transplantation
2-Cell therapies including CAR-T and TIL
3-Drug development in hematologic malignancies
4-Outcomes research
Select Publications:
Al-Juhaishi, T., Dela Cruz, S., Gupta, R., Keiffer, G., Morrison,V. A., Shapira, I., Woods, A., Norsworthy, K., de Claro, R. A.,Theoret, M. R., Garg, R., & Pulte, E. D. (2024). Treatment ofAcute Myeloid Leukemia in the Community Setting. Theoncologist, oyae051. Advance online publication.
https://doi.org/10.1093/oncolo/oyae051
Al-Juhaishi T, Ahmed S. Management of limited-stageHodgkin lymphoma. Hematology Am Soc Hematol EducProgram. 2023 Dec 8;2023(1):500-509. doi:10.1182/hematology.2023000511. PMID: 38066938.
Davis, O., Lessani, C., Kasht, R., Cohoon, A., Ibrahimi, S.,Asch, A., Day, S., &
Al-Juhaishi, T.(2024). Impact of PrimaryDisease Site of Involvement by Early-Stage FollicularLymphoma on Patient Outcomes. Clinical lymphoma,myeloma & leukemia, S2152-2650(24)00269-6. Advanceonline publication.https://doi.org/10.1016/j.clml.2024.07.012
Davis O, Truong D, Day S, Pandey M, Ibrahimi S,Khawandanah M, Holter-Chakrabarty J, Asch A, Al-Juhaishi T. Impact of primary organ site of involvement by peripheralT-cell lymphoma not otherwise specified on survival. CancerMed. 2023 Dec 11. doi: 10.1002/cam4.6743. Epub ahead ofprint. PMID: 38073461.
Malek, A. E.,Al-Juhaishi, T., Milton, D. R., Ramdial, J. L.,Daher, M., Olson, A. L., Srour, S. A., Alatrash, G., Oran, B.,Mehta, R. S., Khouri, I. F., Bashir, Q., Shah, N., Ciurea, S. O.,Rondon, G., Maadani, F., Hosing, C., Marin, D., Kebriaei, P.,Rezvani, K., … Ahmed, S. (2024). Outcomes of toxoplasmosisafter allogeneic hematopoietic stem cell transplantation andthe role of antimicrobial prophylaxis. Bone marrowtransplantation, 59(5), 699–704.
https://doi.org/10.1038/s41409-024-02238-x
Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E,Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, PopatU, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, YoungKH, Khouri IF. Clinical relevance of MYC/BCL2 expressionand cell of origin in patients with diffuse large b-celllymphoma treated with autologous transplant. BoneMarrow Transplant. 2023 Sep;58(9):1000-1007. doi:10.1038/s41409-023-02006-3. Epub 2023 May 18. PMID:37198234.
Al-Juhaishi T, Ahmed S. CAR-T in B-Cell Lymphomas: ThePast, Present, and Future. Clin Lymphoma Myeloma Leuk.2021 Oct 15:S2152-2650(21)02383-1. doi:10.1016/j.clml.2021.10.003.
Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, et al. Real-worldlong-term outcomes in multiple myeloma with VRDinduction, Mel200-conditioned auto-HCT, and lenalidomidemaintenance. Leuk Lymphoma. 2021 Oct 22:1-12. doi:10.1080/10428194.2021.1992763. Epub ahead of print
Al-Juhaishi T, Al-Kindi SG. Outcomes of cardiac diffuse largeB-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol.2021 Jul 26:S0167-5273(21)01188-8. doi:10.1016/j.ijcard.2021.07.043
Al-Juhaishi T, Ahmed S. Selecting the Optimal CAR-T for theTreatment of B-Cell Malignancies. Curr Hematol Malig Rep.2021 Feb 25. doi: 10.1007/s11899-021-00615-7
Koebley SR, Mikheikin A, Leslie K, Guest D, McConnell-WellsW, Lehman JH,
Al Juhaishi T, Zhang X, Roberts CH, Picco L,Toor A, Chesney A, Reed J. Digital Polymerase Chain ReactionPaired with High-Speed Atomic Force Microscopy forQuantitation and Length Analysis of DNA LengthPolymorphisms. ACS Nano. 2020 Nov 10. doi:10.1021/acsnano.0c05897.
Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancingantitumor immunity through checkpoint blockade as atherapeutic strategy in T-cell lymphomas. Blood Adv.2020;4(17):4256-4266.
Al-Juhaishi T, Mckay J, Sindel A, Yazbeck V. Perspectives onchemotherapy for the management of double-hitlymphoma. Expert Opin Pharmacother. 2020;21(6):653-661.
Sindel A, Al-Juhaishi T, Yazbeck V. Marginal ZoneLymphoma: State-of-the-Art Treatment. Curr Treat OptionsOncol. 2019 Dec 5;20(12):90. doi: 10.1007/s11864-019-0687-
Al-Juhaishi T, Khurana A, Shafer D. Therapy-related myeloidneoplasms in lymphoma survivors: Reducing risks. BestPract Res Clin Haematol. 2019 Mar;32(1):47-53. doi:10.1016/j.beha.2019.02.008.
Al-Juhaishi T, Yazbeck V. Choosing the rightpharmacotherapy for non-Hodgkin's lymphoma: does onesize fit all? Expert Opin Pharmacother. 2019 May;20(7):773-775. doi: 10.1080/14656566.2019.1582643.